会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • 퀴놀린 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
    • 喹啉衍生物,其制备方法和药物组合物,包括它们
    • KR101079927B1
    • 2011-11-04
    • KR1020100117355
    • 2010-11-24
    • 동아쏘시오홀딩스 주식회사
    • 손미원이태호최상진백남준이강노김기현김순회
    • C07D217/04A61K31/473A61P1/00
    • PURPOSE: A novel quinoline derivative compounds and a pharmaceutically acceptable salt thereof are provided to promote gastrointestinal motility and to effectively prevent or treat gastrointestinal motility disorders. CONSTITUTION: A quinoline derivative compound is denoted by chemical formula 1. The quinoline derivative compound is (S)-4-oxo-4-(1,2,9,10-tetramethoxy-4,5,6a,7-tetrahydro-dibenzo[de,g]quinoline-6-yl)-butyric acid ethyl ester. A method for preparing the compound of chemical formula 1 comprises a step of a compound of chemical formula 3 or optical isomer thereof with a compound of chemical formula 4 under the presence of a base. A pharmaceutical composition for preventing or treating gastrointestinal movility disorders contains the compound of chemical formula 1, optical isomer thereof, pharmaceutically acceptable salt thereof, hydrate, or solvate thereof.
    • 目的:提供一种新颖的喹啉衍生物及其药学上可接受的盐,以促进胃肠蠕动,并有效预防或治疗胃肠动力障碍。 喹啉衍生物化合物为(S)-4-氧代-4-(1,2,9,10-四甲氧基-4,5,6a,7-四氢 - 二苯并[ [de,g]喹啉-6-基) - 丁酸乙酯。 制备化学式1化合物的方法包括化学式3的化合物或其光学异构体与碱的存在下化学式4的化合物的步骤。 用于预防或治疗胃肠道运动障碍的药物组合物含有化学式1的化合物,其光学异构体,其药学上可接受的盐,水合物或溶剂化物。
    • 8. 发明公开
    • 생분해성 고분자 미립구 및 그 제조방법
    • 一种可生物降解的微生物及其生产方法
    • KR1020100042768A
    • 2010-04-27
    • KR1020080101911
    • 2008-10-17
    • 동아쏘시오홀딩스 주식회사
    • 김태형손미경윤지혜김윤지권인호양희창이건일곽현희강수형
    • A61K9/16C08J3/12C08L67/04
    • A61K47/593A61K38/1703C08J3/12C08L67/04Y10S514/866
    • PURPOSE: A biodegradable polymer microsphere which is able to release pseudin-2 or analog thereof is provided to continuously release the pseudin or pseudin-2 analog and to improve treatment effect for diabetes. CONSTITUTION: A biodegradable polymer microsphere contains pseudin-2 or analog thereof, and biodegradable polymer and continuously releases the pseudin-2 or analog by controlling. The pseudin-2 or analog is natural type, recombination type or synthetic type. The biodegradable polymer is poly-L-lactic acid, poly-D-lactic acid-co-glycolic acid, poly-L-lactic acid-co-glycolic acid, or poly-D,L-lactic acid-co-glycolic acid. An amino acid sequence of the pseudin-2 or analog is one of sequence among sequence numbers 1-7. An agent for preventing and treating diabetes contains the biodegradable polymer microsphere.
    • 目的:提供能够释放假蛋白-2或其类似物的可生物降解的聚合物微球,以连续释放假蛋白或假蛋白-2类似物并改善糖尿病的治疗效果。 构成:可生物降解的聚合物微球含有假蛋白2或其类似物和可生物降解的聚合物,并通过控制连续释放假蛋白-2或类似物。 假蛋白-2或类似物是天然型,重组型或合成型。 生物降解性聚合物是聚-L-乳酸,聚-D-乳酸 - 共 - 乙醇酸,聚-L-乳酸 - 共 - 乙醇酸,或聚-D,L-乳酸 - 共 - 乙醇酸。 假蛋白-2或类似物的氨基酸序列是序列号1-7中的序列之一。 用于预防和治疗糖尿病的药物含有可生物降解的聚合物微球。